دسترسی یکساله به بیش از ۵۰۰ ژورنال روز جهان موجود در سامانه
-
http://medilib.ir
- ﻣﺪﺕ ﺯﻣﺎﻥ : 365 ﺭﻭﺯ
قیمت : 3,800,000 تومان- قیمت ویژه : 1,900,000تومان
COVID-19: A Year on
Chapman, Jeremy R. MD; Baan, Carla C. PhD; Bromberg, J. MD, PhD; Emond, Jean E. MD; Geissler, Edward K. PhD; Kaplan, B. MD; Tullius, Stefan G. MD, PhD
doi : 10.1097/TP.0000000000003544
January 2021 - Volume 105 - Issue 1 - p 1-3
COVID-19: The Patients’ Perspectives
White, David; Gee, Patrick O.; Temple1, Tracey
doi : 10.1097/TP.0000000000003525
January 2021 - Volume 105 - Issue 1 - p 4-5
Organ Donation in the Eastern Mediterranean Region
Bader, Feras MD, MS, FACC, FHFSA1; Manla, Yosef MD1; Hammouri, Marwa MD2; Attallah, and Nizar MD
doi : 10.1097/TP.0000000000003375
January 2021 - Volume 105 - Issue 1 - p 6-9
Research Highlights
Todd, Jamie L. MD1; Luo, Xunrong MD
doi : 10.1097/TP.0000000000003555
January 2021 - Volume 105 - Issue 1 - p 10-11
Toward Improved and Standardized Diagnostic Pipelines in Transplantation
Kurian, Sunil M. PhD1,2; Whisenant, Thomas C. PhD3; Marsh, Christopher L. MD
doi : 10.1097/TP.0000000000003438
January 2021 - Volume 105 - Issue 1 - p 12-13
Summary of International Recommendations for Donation and Transplantation Programs During the Coronavirus Disease Pandemic
Weiss, Matthew J. MD1,2,3,4; Lalani, Jehan MHA4; Patriquin-Stoner, Chelsea BA3; Dieudé, Mélanie PhD3,5; Hartell, David MA4; Hornby, Laura MSc3,4,6; Shemie, Sam D. MD4,3,7; Wilson, Lindsay MHA4; Mah, Allison MD
doi : 10.1097/TP.0000000000003520
January 2021 - Volume 105 - Issue 1 - p 14-17
The COVID-19 pandemic has disrupted all aspects of the international organ donation and transplantation (ODT) system. Multiple organizations have developed guidance, but to date, no comparative summary has emerged to understand differences in existing recommendations.
Big Data in Transplantation Practice—the Devil Is in the Detail—Fontan-associated Liver Disease
Kim, Michelle H. MD1; Nguyen, Ailene BS1; Lo, Mary MS2; Kumar, Subramanyan Ram MD, PhD3,4; Bucuvalas, John MD5; Glynn, Earl F. MS6; Hoffman, Mark A. PhD6; Fischer, Ryan MD7; Emamaullee, Juliet MD, PhD, FRCSC
doi : 10.1097/TP.0000000000003308
January 2021 - Volume 105 - Issue 1 - p 18-22
As a result of the Fontan procedure, the prognosis of congenital single-ventricle heart disease has improved, with many affected children surviving into adulthood. However, the unanticipated consequences of chronic exposure to Fontan hemodynamics have revealed a new set of secondary noncardiac complications. Fontan-associated liver disease (FALD) is characterized by progressive hepatic fibrosis in nearly all patients post-Fontan, with the potential to develop cirrhosis, hepatocellular carcinoma, and the need for liver transplantation. A lack of data regarding FALD-related prognosis makes consideration of indications for and timing of heart alone versus combined heart-liver transplantation challenging.
The Science Is Only as Good as the Data: The Case of Fontan-associated Liver Disease
King, Elizabeth A. MD, PhD1; Brennan, Daniel C. MD, FACP
doi : 10.1097/TP.0000000000003329
January 2021 - Volume 105 - Issue 1 - p 23-24
Opioid Use and Liver Transplantation
Braun, Hillary J. MD1; Ascher, Nancy L. MD, PhD1
doi : 10.1097/TP.0000000000003156
January 2021 - Volume 105 - Issue 1 - p 25-26
The 3P’s of Transplant Modeling to Inform Clinical Decision-making: Predictability, Probability, and Possibility
Lim, Wai H. MBBS, PhD1,2; Wong, Germaine MBBS, PhD
doi : 10.1097/TP.0000000000003204
January 2021 - Volume 105 - Issue 1 - p 27-28
Organ Donation and Transplantation During the COVID-19 Pandemic: A Summary of the Spanish Experience
Dom?nguez-Gil, Beatriz MD, PhD1; Fern?ndez-Ruiz, Mario MD, PhD2; Hern?ndez, Domingo MD, PhD3; Crespo, Marta MD, PhD4; Colmenero, Jordi MD, PhD5; Coll, Elisabeth MD, PhD1; Rubio, Juan José MD, PhD
doi : 10.1097/TP.0000000000003528
January 2021 - Volume 105 - Issue 1 - p 29-36
Spain has been amongst the countries most affected by the COVID-19 pandemic, which has posed significant challenges to the donation and transplantation program. Despite a dramatic decrease of donation and transplantation activities during the critical early weeks of the outbreak, the program has recovered and is learning to cope with COVID-19.
COVID-19 and Solid Organ Transplantation: A Review Article
Azzi, Yorg MD1; Bartash, Rachel MD2; Scalea, Joseph MD3; Loarte-Campos, Pablo MD1; Akalin, Enver MD, FAST, FASN
doi : 10.1097/TP.0000000000003523
January 2021 - Volume 105 - Issue 1 - p 37-55
The coronavirus pandemic has significantly impacted solid organ transplantation (SOT). Early in the outbreak period, transplant societies recommended suspending living kidney transplant programs in communities with widespread transmission to avoid exposing recipients to increased risk of immunosuppression, while recommendations were made to reserve deceased-donor kidney transplantation for likely life-saving indications.
COVID-19 Therapeutics for Solid Organ Transplant Recipients; 6 Months Into the Pandemic: Where Are We Now?
Avery, Robin K. MD, FIDSA, FAST
doi : 10.1097/TP.0000000000003519
January 2021 - Volume 105 - Issue 1 - p 56-60
As in the general population with coronavirus 2019 (COVID-19) infection, therapeutic interventions in solid organ transplant (SOT) recipients have evolved over time. The preceding 6 months of the pandemic can be divided into 2 main therapeutic eras: the early era and the later era. The first era was characterized by the widespread use of drugs such as hydroxychloroquine with or without azithromycin, lopinavir–ritonavir, and tocilizumab.
Solid Organ Transplantation in the Era of COVID-19: Lessons from France
Zaidan, Mohamad MD, PhD1,2,3; Legendre, Christophe MD
doi : 10.1097/TP.0000000000003536
January 2021 - Volume 105 - Issue 1 - p 61-66
Coronavirus disease 2019 (COVID-19) outbreak has significantly upended solid organ transplant (SOT) practice around the world. Early reports confirmed the heavy burden of COVID-19 in SOT recipients with mortality rates reaching up to 35%. Because most transplant recipients harbored multiple comorbidities known to be associated with a severe course of COVID-19, the true impact of immunosuppression by itself remained an unsolved issue. Transplant societies have initially recommended to postpone nonurgent renal transplantations, while trying to maintain life-saving transplant programs, such as heart, lung, and liver transplantations.
Immune Checkpoint Inhibitors in Transplantation—A Case Series and Comprehensive Review of Current Knowledge
Delyon, Julie MD, PhD1; Zuber, Julien MD, PhD2; Dorent, Richard MD3; Poujol-Robert, Armelle MD4; Peraldi, Marie-Noelle MD, PhD5; Anglicheau, Dany MD, PhD2; Lebbe, Celeste MD, PhD
doi : 10.1097/TP.0000000000003292
January 2021 - Volume 105 - Issue 1 - p 67-78
Cancer is a leading cause of morbidity and deaths in solid organ transplant recipients. In immunocompetent patients, cancer prognosis has been dramatically improved with the development of immune checkpoint inhibitors (ICI), as programmed cell death protein 1/programmed death-ligand 1 and cytotoxic T lymphocyte–associated antigen 4 inhibitors, that increase antitumor immune responses. ICI has been developed outside of the scope of transplantation because of the theoretical risk of graft rejection, which has later been confirmed by the publication of several cases and small series.
Development and Validation of a Multiplex, Bead-based Assay to Detect Antibodies Directed Against SARS-CoV-2 Proteins
Bray, Robert A. PhD1; Lee, Jar-How PhD2; Brescia, Peter BS3; Kumar, Deepali MD4; Nong, Thoa BS3; Shih, Remi PhD3; Woodle, E. Steve MD5; Maltzman, Jonathan S. MD, PhD6,7; Gebel, Howard M. PhD
doi : 10.1097/TP.0000000000003524
January 2021 - Volume 105 - Issue 1 - p 79-89
Transplant recipients who develop COVID-19 may be at increased risk for morbidity and mortality. Determining the status of antibodies against SARS-CoV-2 in both candidates and recipients will be important to understand the epidemiology and clinical course of COVID-19 in this population. While there are multiple tests to detect antibodies to SARS-CoV-2, their performance is variable. Tests vary according to their platforms and the antigenic targets which make interpretation of the results challenging. Furthermore, for some assays, sensitivity and specificity are less than optimal. Additionally, currently available serological tests do not exclude the possibility that positive responses are due to cross reactive antibodies to community coronaviruses rather than SARS-CoV-2.
A Report of 85 Cases of COVID-19 and Abdominal Transplantation From a Single Center: What Are the Associated Factors With Death Among Organ Transplantation Patients
Ali Malekhosseini, Seyed MD1; Nikoupour, Hamed MD1; Gholami, Siavash MSc1; Shamsaeefar, Alireza MD1; Arasteh, Peyman MD, MPH1; Kazemi, Kourosh MD1; Dehghani, Masood MD1; Eghlimi, Hesameddin MD1; Raeisi Shahraki, Hadi PhD2; Roozbeh, Jamshid MD3; Rezaianzadeh, Abbas MD, PhD1; Nikeghbalian, Saman MD
doi : 10.1097/TP.0000000000003470
January 2021 - Volume 105 - Issue 1 - p 90-99
In this study, we report the epidemiology of COVID-19 among recipients of organ transplantation and evaluate associated factors with death.
Prevalence and Patterns of Opioid Use Before and After Liver Transplantation
Cron, David C. MD, MS1,2; Tincopa, Monica A. MD, MSc1,3; Lee, Jay S. MD1,4; Waljee, Akbar K. MD, MS1,3,5; Hammoud, Ali BS4; Brummett, Chad M. MD1,6; Waljee, Jennifer F. MD, MPH, MS1,4; Englesbe, Michael J. MD1,4; Sonnenday, Christopher J. MD, MHS
doi : 10.1097/TP.0000000000003155
January 2021 - Volume 105 - Issue 1 - p 100-107
Opioid use in liver transplantation is poorly understood and has potential associated morbidity.
Initial Report From a Swedish High-volume Transplant Center After the First Wave of the COVID-19 Pandemic
Felldin, Marie MD, PhD1; S?fteland, John Mackay MD, PhD1,2; Magnusson, Jesper MD, PhD1; Ekberg, Jana MD1; Karason, Kristjan MD, PhD1,3; Schult, Andreas MD1,3; Larsson, Hillevi MD, PhD4,5; Oltean, Mihai MD, PhD1,2; Friman, Vanda MD, PhD
doi : 10.1097/TP.0000000000003436
January 2021 - Volume 105 - Issue 1 - p 108-114
Solid organ transplant (SOT) recipients may be more vulnerable to coronavirus disease 2019 (COVID-19). Data on the clinical course of COVID-19 in immunosuppressed patients are limited, and the optimal management strategy for these patients is yet unclear.
Outcomes of Renal Transplant Recipients With SARS-CoV-2 Infection in the Eye of the Storm: A Comparative Study With Waitlisted Patients
Mohamed, Ismail H. MD, FRCS1; Chowdary, Prashanth B. MRCS1; Shetty, Shraddha MRCS1; Sammartino, Cinzia FRCS1; Sivaprakasam, Rajesh FRCS1; Lindsey, Ben FRCS1; Thuraisingham, Raj FRCP1; Yaqoob, Muhammad M. PhD, FRCP1,2; Khurram, Muhammad A. PhD, FRCS
doi : 10.1097/TP.0000000000003406
January 2021 - Volume 105 - Issue 1 - p 115-120
Patients with chronic kidney disease stage 5 and those on immunosuppression are particularly vulnerable and are shielded as per public health strategy. We present our experience of coronavirus disease 2019 (COVID-19) transplant patients in one of the most affected parts of the UK with direct comparison to waitlisted patients.
Coronavirus Disease-19: Disease Severity and Outcomes of Solid Organ Transplant Recipients: Different Spectrums of Disease in Different Populations?
Ali, Tariq MD1; Al-Ali, Ali MD1; Fajji, Layal BSN1; Hammad, Ehab MD1; Nazmi, Ahmed MD1; Alahmadi, Ibrahim MBBS1; Aleid, Hassan MD1; Ullah, Asad MD1; Shah, Yaser FRCP1; Broering, Dieter PhD
doi : 10.1097/TP.0000000000003433
January 2021 - Volume 105 - Issue 1 - p 121-127
Coronavirus disease-19 (COVID-19) is associated with significant mortality. The elderly, patients with comorbidities, and solid organ transplant (SOT) recipients are particularly at risk. We observed a low incidence of severe disease in our population and aimed to determine the outcomes of COVID-19 (disease severity/intensive care unit [ICU] admissions/mortality) in SOT recipients.
COVID-19 Outcomes Among Solid Organ Transplant Recipients: A Case-control Study
Sharma, Pratima MD, MS1; Chen, Vincent MD, MS1; Fung, Christopher M. MD2; Troost, Jonathan P. PhD3; Patel, Vaiibhav N. MD1; Combs, Michael MD1; Norman, Silas MD1; Garg, Puneet MD1; Colvin, Monica MD1; Aaronson, Keith MD, MS1; Sonnenday, Christopher J. MD, MHS4; Golob, Jonathan L. MD, PhD1; Somers, Emily C. PhD, ScM1,5; Doshi, Mona M. MD
doi : 10.1097/TP.0000000000003447
January 2021 - Volume 105 - Issue 1 - p 128-137
Solid organ transplant (SOT) recipients are considered to be “vulnerable” to COVID-19 infection due to immunosuppression. To date, there are no studies that compared the disease severity of COVID-19 in SOT recipients with nontransplant patients.
COVID-19 in Solid Organ Transplantation: A Matched Retrospective Cohort Study and Evaluation of Immunosuppression Management
Miarons, Marta PharmD, PhD1; Larrosa-Garc?a, Mar?a PharmD1; Garc?a-Garc?a, Sonia PharmD1; Los-Arcos, Ibai MD, PhD2; Moreso, Francesc MD, PhD3; Berastegui, Cristina MD, PhD4; Castells, Llu?s MD, PhD5,6; Pérez-Hoyos, Santiago PhD7; Varela, Javier PharmD1; Pau-Parra, Alba PharmD1; Var?n-Galcera, Carlota PharmD1; Parramon-Teixid?, Carlos-Javier PharmD1; Mart?nez-Casanova, Javier PharmD1; Domènech, Laura PharmD1; Garc?a-Ortega, Patricia PharmD1; S?nchez-Sancho, Pablo PharmD1; Alonso-Mart?nez, Carla PharmD1; G?mez-Ganda, Laura PharmD1; Roch-Santed, Maria PharmD1; Gracia-Moya, Ariadna PharmD1; Del-Rio-Gutiérrez, José-Manuel PharmD1; Guillén-Del-Castillo, Alfredo MD, PhD8; Sans-Pola, Carla MD9; Ant?n, Andrés MD, PhD10; Montoro, Bruno PharmD, PhD1; Gorgas-Torner, Maria-Queralt PharmD, PhD1; on behalf of the Vall d’Hebron COVID-19 Working Group
doi : 10.1097/TP.0000000000003460
January 2021 - Volume 105 - Issue 1 - p 138-150
The epidemiological and clinical characteristics of solid organ transplant (SOT) patients during the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) epidemic remains unclear. We conducted a matched retrospective cohort study to compare clinical outcomes among SOT recipients with the general population and to assess immunosuppression management.
Identification of Patient Characteristics Associated With SARS-CoV-2 Infection and Outcome in Kidney Transplant Patients Using Serological Screening
Willicombe, Michelle MD, MRCP1,2; Gleeson, Sarah MB, BCh, BAO2; Clarke, Candice MB, BS, MRCP1,2; Dor, Frank MD, PhD, FEBS, FRCS2; Prendecki, Maria PhD, MRCP1,2; Lightstone, Liz PhD, MRCP1,2; Lucisano, Gaetano MD2; McAdoo, Stephen PhD, MRCP1,2; Thomas, David PhD, MRCP1,2; on behalf of the ICHNT Renal COVID Group
doi : 10.1097/TP.0000000000003526
January 2021 - Volume 105 - Issue 1 - p 151-157
From population studies, solid organ transplant recipients are at increased risk of mortality from RT-PCR confirmed COVID-19 infection. The risk factors associated with infection acquisition and mortality in transplant recipients using serological data have not been reported.
Biomarkers of Cytokine Release Syndrome Predict Disease Severity and Mortality From COVID-19 in Kidney Transplant Recipients
Benotmane, Ilies MD1,2,3; Perrin, Peggy MD1,3; Vargas, Gabriela Gautier MD1; Bassand, Xavier MD1; Keller, Nicolas MD4; Lavaux, Thomas MD5; Ohana, Mickael MD6; Bedo, Dimitri1; Baldacini, Clément1; Sagnard, Mylene1; Bozman, Dogan-Firat MD1; Chiesa, Margaux Della1; Cognard, Noëlle MD1; Olagne, Jérôme MD1; Delagreverie, Héloïse MD, PhD2; Marx, David MD1; Heibel, Françoise MD1; Braun, Laura MD1; Moulin, Bruno MD, PhD1,3; Fafi-Kremer, Samira MD, PhD2,3; Caillard, Sophie MD, PhD
doi : 10.1097/TP.0000000000003480
January 2021 - Volume 105 - Issue 1 - p 158-169
Data on coronavirus disease 2019 (COVID-19) in immunocompromised kidney transplant recipients (KTR) remain scanty. Although markers of inflammation, cardiac injury, and coagulopathy have been previously associated with mortality in the general population of patients with COVID-19, their prognostic impact amongst KTR with severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection has not been specifically investigated.
Early Changes in Kidney Transplant Immunosuppression Regimens During the COVID-19 Pandemic
Bae, Sunjae KMD, PhD1,2; McAdams-DeMarco, Mara A. PhD1,2; Massie, Allan B. PhD1,2; Ahn, JiYoon B. KMD, MPH1; Werbel, William A. MD3; Brennan, Daniel C. MD3; Lentine, Krista L. MD, PhD4; Durand, Christine M. MD3,5; Segev, Dorry L. MD, PhD
doi : 10.1097/TP.0000000000003502
January 2021 - Volume 105 - Issue 1 - p 170-176
Kidney transplant recipients have higher risk of infectious diseases due to their reliance on immunosuppression. During the current COVID-19 pandemic, some clinicians might have opted for less potent immunosuppressive agents to counterbalance the novel infectious risk. We conducted a nationwide study to characterize immunosuppression use and subsequent clinical outcomes during the first 5 months of COVID-19 pandemic in the United States.
COVID-19 in Lung Transplant Recipients
Messika, Jonathan MD, PhD1,2,3; Eloy, Philippine PharmD4,5; Roux, Antoine MD, PhD3,6,7; Hirschi, Sandrine MD8; Nieves, Ana MD9; Le Pavec, Jérôme MD, PhD10,11,12; Sénéchal, Agathe MD13; Saint Raymond, Christel MD14; Carlier, Nicolas MD15; Demant, Xavier MD16; Le Borgne, Aurélie MD17; Tissot, Adrien MD18; Debray, Marie-Pierre MD19; Beaumont, Laurence MD6; Renaud-Picard, Benjamin MD8; Reynaud-Gaubert, Martine MD, PhD9; Mornex, Jean-François MD, PhD13,20; Falque, Loïc MD14; Boussaud, Véronique MD15; Jougon, Jacques MD, PhD16; Mussot, Sacha MD10,11,12; Mal, Hervé MD, PhD1,2; for the French Group of Lung Transplantation
doi : 10.1097/TP.0000000000003508
January 2021 - Volume 105 - Issue 1 - p 177-186
A concern about the susceptibility of immunocompromised patients to the worldwide pandemic of coronavirus disease 2019 (COVID-19) has been raised. We aimed at describing COVID-19 infections in the French cohort of lung transplant (LT) patients.
Trends in Lung Transplantation Practices Across the United States During the COVID-19 Pandemic
Chan, Ernest G. MD, MPH1; Chan, Patrick G. MD, MPH1; Harano, Takashi MD1; Ryan, John P. PhD1; Morrell, Matthew R. MD2; Sanchez, Pablo G. MD, PhD
doi : 10.1097/TP.0000000000003522
January 2021 - Volume 105 - Issue 1 - p 187-192
The purpose of this study is to examine the effects of the coronavirus disease 2019 (COVID-19) pandemic on adult lung transplants and report practice changes in the United States.
HLA and AB0 Polymorphisms May Influence SARS-CoV-2 Infection and COVID-19 Severity
Amoroso, Antonio MD1,2; Magistroni, Paola Dphys2; Vespasiano, Francesca DLaw3; Bella, Antonino Dstat4; Bellino, Stefania PhD4; Puoti, Francesca BD3; Alizzi, Silvia BD2; Vaisitti, Tiziana PhD1; Boros, Stefano4; Grossi, Paolo Antonio MD5; Trapani, Silvia MD3; Lombardini, Letizia MD3; Pezzotti, Patrizio Dstat4; Deaglio, Silvia MD, PhD1,2; Brusaferro, Silvio MD6; Cardillo, Massimo MD3; on behalf of the Italian Network of Regional Transplant Coordinating Centers
doi : 10.1097/TP.0000000000003507
January 2021 - Volume 105 - Issue 1 - p 193-200
SARS-CoV-2 infection is heterogeneous in clinical presentation and disease evolution. To investigate whether immune response to the virus can be influenced by genetic factors, we compared HLA and AB0 frequencies in organ transplant recipients and waitlisted patients according to presence or absence of SARS-CoV-2 infection.
Acute Kidney Injury in a Predominantly African American Cohort of Kidney Transplant Recipients With COVID-19 Infection
Shrivastava, Pritika MD1; Prashar, Rohini MD1; Khoury, Nadeen MD1; Patel, Anita MD1,2; Yeddula, Sirisha3; Kitajima, Toshihiro MD3; Nagai, Shunji MD2,3; Samaniego, Milagros MD
doi : 10.1097/TP.0000000000003498
January 2021 - Volume 105 - Issue 1 - p 201-205
Renal involvement in severe or critical acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection is frequent. Acute kidney injury (AKI) in African American (AA) kidney transplant recipients (KTRs) with COVID-19 is not well described. We report our experience with a predominantly AA cohort (79%) of KTRs with COVID-19 infections in the Detroit Metropolitan area.
De Novo Focal and Segmental Glomerulosclerosis After COVID-19 in a Patient With a Transplanted Kidney From a Donor With a High-risk APOL1 Variant
Oniszczuk, Julie MD, PhD1,2,*; Moktefi, Anissa MD, PhD2,3,*; Mausoleo, Aude MD1,2; Pallet, Nicolas MD, PhD4; Malard-Castagnet, Stephanie MD5; Fourati, Slim MD, PhD6,7; El Karoui, Khalil MD, PhD1,2; Sahali, Dil MD, PhD1,2; Stehlé, Thomas MD1,2; Boueilh, Anna MD1,2; Verpont, Marie-Christine MSc8,9; Matignon, Marie MD, PhD1,2; Buob, David MD, PhD10; Grimbert, Philippe MD, PhD1,2; Audard, Vincent MD, PhD
doi : 10.1097/TP.0000000000003432
January 2021 - Volume 105 - Issue 1 - p 206-211
There is compelling evidence that renal complications in a native kidney are a major concern in patients infected with severe acute respiratory syndrome coronavirus 2, the causal agent of coronavirus disease 2019 (COVID-19). The spectrum of renal lesions observed on renal grafts in this context remains to be determined.
Mortality Rates in Transplant Recipients and Transplantation Candidates in a High-prevalence COVID-19 Environment
Mamode, Nizam FRCS1; Ahmed, Zubir FRCS1; Jones, Gareth FRCP2; Banga, Neal FRCS2; Motallebzadeh, Reza FRCS2; Tolley, Hannah BSc3; Marks, Steve FRCPCH4; Stojanovic, Jelena FRCPCH4; Khurram, Muhammad A. FRCS5; Thuraisingham, Raj FRCP5; Popoola, Joyce PhD6; Ghazanfar, Abbas FRCS6; Game, David FRCP1; Sran, Kiran FRCS1; Dor, Frank J.M.F. PhD7,8; Lucisano, Gaetano MD7; Sinha, Manish PhD1; Olsburgh, Jonathon FRCS1; Willicombe, Michelle MRCP
doi : 10.1097/TP.0000000000003533
January 2021 - Volume 105 - Issue 1 - p 212-215
The risk of COVID-19 infection in transplant recipients (TRs) is unknown. Patients on dialysis may be exposed to greater risk of infection due to an inability to isolate. Consideration of these competing risks is important before restarting suspended transplant programs. This study compared outcomes in kidney and kidney/pancreas TRs with those on the waiting list, following admission with COVID-19 in a high-prevalence region.
Incidence and Outcomes of COVID-19 in Kidney and Liver Transplant Recipients With HIV: Report From the National HOPE in Action Consortium
Mehta, Sapna A. MD1; Rana, Meenakshi M. MD2; Motter, Jennifer D. MHS3; Small, Catherine B. MD4; Pereira, Marcus R. MD5; Stosor, Valentina MD6; Elias, Nahel MD7; Haydel, Brandy CCRC8; Florman, Sander MD8; Odim, Jonah MD9; Morsheimer, Megan MD9; Robien, Mark MD9; Massie, Allan B. PhD3; Brown, Diane RN, MSN10; Boyarsky, Brian J. MD3; Garonzik-Wang, Jacqueline MD, PhD3; Tobian, Aaron A.R. MD, PhD11; Werbel, William A. MD10; Segev, Dorry L. MD, PhD3; Durand, Christine M. MD10; on behalf of the HOPE in Action Investigators
doi : 10.1097/TP.0000000000003527
January 2021 - Volume 105 - Issue 1 - p 216-224
Transplant recipients with HIV may have worse outcomes with coronavirus disease 2019 (COVID-19) due to impaired T-cell function coupled with immunosuppressive drugs. Alternatively, immunosuppression might reduce inflammatory complications and/or antiretrovirals could be protective.
Dallas UtErus Transplant Study: Early Outcomes and Complications of Robot-assisted Hysterectomy for Living Uterus Donors
Johannesson, Liza MD, PhD1; Koon, E. Colin MD2; Bayer, Johanna MD1; McKenna, Gregory J. MD1; Wall, Anji MD1; Fernandez, Hoylan MD1; Martinez, Eric J. MD1; Gupta, Amar MD1; Ruiz, Richard MD1; Onaca, Nicholas MD1; Testa, Giuliano MD
doi : 10.1097/TP.0000000000003211
January 2021 - Volume 105 - Issue 1 - p 225-230
Uterus transplantation is a treatment for absolute uterine infertility and can be performed with living and deceased donors. Given the safety and increased utilization of robotic assistance with other gynecologic and transplant donor operations, we adopted a robot-assisted approach to donor hysterectomy. This study compared early outcomes and morbidity of the robot-assisted approach to donor hysterectomy with the traditionally performed open approach and addressed whether the robot-assisted approach is safe and offers advantages for the donor.
Bone Mineral Density and Aortic Calcification: Evidence for a Bone-vascular Axis After Kidney Transplantation
Sotomayor, Camilo G. MD1,2; Benjamens, Stan BSc3,4; Gomes-Neto, Ant?nio W. MD1; Pol, Robert A. MD, PhD3; Groothof, Dion BSc1; te Velde-Keyzer, Charlotte A. MD, PhD1; Chong, Guillermo MD5; Glaudemans, Andor W.J.M. MD, PhD4; Berger, Stefan P. MD, PhD1; Bakker, Stephan J.L. MD, PhD1; Slart, Riemer H.J.A. MD, PhD
doi : 10.1097/TP.0000000000003226
January 2021 - Volume 105 - Issue 1 - p 231-239
Chronic kidney disease mineral and bone disorders (CKD-MBD) and vascular calcification are often seen in kidney transplantation recipients (KTR). This study focused on the bone–vascular axis hypothesis, the pathophysiological mechanisms driving both bone loss and vascular calcification, supported by an association between lower bone mineral density (BMD) and higher risk of vascular calcification.
Creating Options for Difficult-to-match Kidney Transplant Candidates
de Klerk, Marry PhD1; Kal-van Gestel, Judith A. Drs1; van de Wetering, Jacqueline MD, PhD1; Kho, Marcia L. MD1; Middel-de Sterke, Sandra1; Betjes, Michiel G.H. MD, PhD1; Zuidema, Willij C.1; Roelen, Dave PhD2; Glorie, Kristiaan PhD3; Roodnat, Joke I. MD, PhD
doi : 10.1097/TP.0000000000003203
January 2021 - Volume 105 - Issue 1 - p 240-248
Most transplantation centers recognize a small patient population that unsuccessfully participates in all available, both living and deceased donor, transplantation programs for many years: the difficult-to-match patients. This population consists of highly immunized and/or ABO blood group O or B patients.
Is There Sufficient Evidence Justifying Limited Access of Jehovah’s Witness Patients to Kidney Transplantation?
Carvalho Fiel, David MD1; Nunes Ficher, Klaus MD2; Bernardi Taddeo, Julia PharmD2; Linhares Silva, Kamilla PharmD, MD2; Rosso Felipe, Cl?udia PharmD2; Aguiar, Wilson MD, PhD3; Daniel Braz Cardone, Jose MD4; Foresto, Renato Demarchi MD2; Tedesco-Silva, Hélio Jr MD, PhD2; Medina-Pestana, José MD, PhD
doi : 10.1097/TP.0000000000003227
January 2021 - Volume 105 - Issue 1 - p 249-254
Jehovah’s Witnesses (JWs) refuse blood transfusions due to religious issues. This situation may impact kidney transplantation (KT) outcomes in case of hemorrhagic complications. We evaluated demographic characteristics of this population, hematologic safety, and graft outcomes.
Multilevel Correlates of Immunosuppressive Nonadherence in Kidney Transplant Patients: The Multicenter ADHERE BRAZIL Study
Sanders-Pinheiro, Helady MD, PhD1; Colugnati, Fernando A.B. PhD1; Denhaerynck, Kris RN, PhD2; Marsicano, Elisa O. RN1; Medina, José O.P. MD, PhD3; De Geest, Sabina S, RN, PhD2,4; ADHERE BRAZIL Study Team The ADHERE BRAZIL study team includes the following individuals
doi : 10.1097/TP.0000000000003214
January 2021 - Volume 105 - Issue 1 - p 255-266
Immunosuppressive nonadherence is a risk factor for worse outcomes after kidney transplantation (KT). Brazil, having the world’s largest public, fully covered transplantation system and the second-highest KT volume worldwide, provides a unique setting for studying multilevel correlates of nonadherence (patient, healthcare provider, transplant center, and healthcare system levels) independent of patients’ financial burden.
Kidney Transplantation in Patients With SARS-CoV-2 Infection: A Case Series Report
Viana, Laila A. MD1; Cristelli, Marina P. MD1; Ficher, Klaus N. MD1; Rezende, Juliana T. MD1; Villanueva, Luc?a A.A. MD1; Santos, Daniel W.C.L. MD1; Fernandes, Ruan MD1; Foresto, Renato D. MD1; Tedesco-Silva, Helio PhD1; Medina-Pestana, José PhD1
doi : 10.1097/TP.0000000000003521
January 2021 - Volume 105 - Issue 1 - p e1-e3
Successful Living Kidney Donation After COVID-19 Infection
Safa, Kassem MD1,2,3; Elias, Nahel MD1,3,4; Gilligan, Hannah M. MD1,2,3; Kawai, Tatsuo MD1,3,4; Kotton, Camille N. MD
doi : 10.1097/TP.0000000000003510
January 2021 - Volume 105 - Issue 1 - p e4-e5
COVID-19 in Solid Organ Transplant Recipients: Observations From Connecticut
Kutzler, Heather L. PharmD1; Poulos, Constantine M. MD2; Cheema, Faiqa MD1,3; O’Sullivan, David M. PhD4; Ali, Ayyaz MD1,3,5; Ebcioglu, Zeynep MD1,3; Einstein, Michael MD1,3; Feingold, Andrew D. MD1,3,5; Gluck, Jason MD1,3,5; Hammond, Jonathan A. MD1,2,5; Jaiswal, Abhishek MD1,3,5; Lawlor, Michael T. MD1,3; Morgan, Glyn MD1,2; Radojevic, Joseph A. MD1,3,5; Rochon, Caroline MD1,2; Sheiner, Patricia MD1,2; Singh, Joseph U. MD1,3; Sotil, Eva U. MD1,3; Swales, Colin MD1,3; Ye, Xiaoyi MD1,3; Serrano, Oscar K. MD
doi : 10.1097/TP.0000000000003495
January 2021 - Volume 105 - Issue 1 - p e6-e8
The Unpredictable Outcome of SARS-CoV-2 in Kidney Transplant Recipients With HIV-infection
de Sandes-Freitas, Tain? Veras MD, PhD1,2; Cristelli, Marina Pontello MD, PhD3; Neri, Beatriz de Oliveira MD2; Guedes, Andreza Liara Machado de Oliveira MD2; Esmeraldo, Ronaldo de Matos MD2; Garcia, Valter Duro MD, PhD4; Dal Pr?, Ronivan Luis PharmD4; Suassuna, José Herm?genes Rocco MD, PhD5; Rioja, Suzimar da Silveira MD, PhD5; Zanocco, Juliana Aparecida MD6; Claudino, Auro Buffani MD6; Medina-Pestana, José Osmar MD, PhD3,7; Tedesco-Silva, Hélio MD, PhD
doi : 10.1097/TP.0000000000003529
January 2021 - Volume 105 - Issue 1 - p e9-e10
A Short Period of Normothermic Machine Perfusion May Not Be Able to Predict Primary Nonfunction in Uncontrolled Circulatory Death Kidneys
Hosgood, Sarah A. PhD1; Nicholson, Michael L. DSc
doi : 10.1097/TP.0000000000003415
January 2021 - Volume 105 - Issue 1 - p e11-e12
Correspondence: The First Asian Kidney Transplantation Prediction Models for Long-term Patient and Allograft Survival
Miyauchi, Takamasa MD1,2; Yazawa, Masahiko MD1; Molnar, Miklos Z. MD, PhD3,4; Shibagaki, Yugo MD
doi : 10.1097/TP.0000000000003440
January 2021 - Volume 105 - Issue 1 - p e13-e14
The Authors’ Reply: Correspondence: The First Asian Kidney Transplantation Prediction Models for Long-Term Patient and Allograft Survival
Udomkarnjananun, Suwasin MD1,2,3; Townamchai, Natavudh MD1,2,3; Kerr, Stephen J. PhD4; Tasanarong, Adis MD, PhD5; Noppakun, Kajohnsak MD6; Lumpaopong, Adisorn MD7; Prommool, Surazee MD8; Supaporn, Thanom MD9; Avihingsanon, Yingyos MD1,2,3; Praditpornsilpa, Kearkiat MD1; Eiam-ong, Somchai MD
doi : 10.1097/TP.0000000000003441
January 2021 - Volume 105 - Issue 1 - p e15-e16
Ex Vivo Lung Perfusion Improves the Inflammatory Signaling Profile of the Porcine Donor Lung Following Transplantation: Erratum
doi : 10.1097/TP.0000000000003553
January 2021 - Volume 105 - Issue 1 - p e17
Novel Use of Normothermic Machine Perfusion of the Liver: A Strategy to Mitigate Unexpected Clinical Events: Erratum
doi : 10.1097/TP.0000000000003554
January 2021 - Volume 105 - Issue 1 - p e17
